Blog
RSS FeedPosted by Michael Wonder on 10 Mar 2022
AARP launches new ad showing the impact of Congress’ failure to act on prescription drug prices
10 March 2022 - AARP launched new television and digital advertising featuring Larry Zarzecki, a retired law enforcement officer with Parkinson’s ...
Posted by Michael Wonder on 10 Mar 2022
Legislation would set expiration for FDA’s accelerated approvals
9 March 2022 - New legislation, introduced by a top Democrat in the House of Representatives, would codify the U.S. ...
Posted by Michael Wonder on 10 Mar 2022
When desperate patients go to court for unproven treatments - the battle for hospital independence
9 March 2022 - During the COVID-19 pandemic, patients have asked courts to compel hospitals to administer unproven therapies, including ivermectin. ...
Posted by Michael Wonder on 09 Mar 2022
More Government regulation of biopharma would harm patients and the economy
8 March 2022 - The United States leads the world in creating the new drugs and vaccines that cure or control ...
Posted by Michael Wonder on 08 Mar 2022
Vaccine approval before Phase 3 trial results: a consequence of vaccine access inequity
2 March 2022 - The final Phase 3 clinical data for CanSino Biologics' adenovirus type 5 vector vaccine show that Ad5-nCoV ...
Posted by Michael Wonder on 08 Mar 2022
FDA effort to improve clinical trial diversity failed to make a difference for Black patients, study finds
7 March 2022 - Six years ago, the U.S. FDA launched a five year action plan to improve the diversity and ...
Posted by Michael Wonder on 08 Mar 2022
FDA offers funding for biosimilar regulatory science pilot
7 March 2022 - The US FDA is offering funding for several research proposals under the regulatory science pilot for ...
Posted by Michael Wonder on 07 Mar 2022
Key Democrat moves to crack down on FDA accelerated approvals
7 March 2022 - A powerful Democratic lawmaker has introduced a bill that would dramatically rein in the Food and ...
Posted by Michael Wonder on 07 Mar 2022
Rezafungin awarded promising innovation medicine designation by the UK’s Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis
3 March 2022 - Rezafungin is a next-generation once weekly echinocandin being developed for both the treatment and prevention of serious ...
Posted by Michael Wonder on 06 Mar 2022
Australian COVID nasal spray not on shop shelves amid TGA dispute
4 March 2022 - Melbourne start-up Starpharma is at loggerheads with the medicines regulator over the approvals process for its ...
Posted by Michael Wonder on 06 Mar 2022
We can't pass up the opportunity to lower drug prices
3 March 2022 - When Americans go to the pharmacy to pick up their prescription drugs, they’re too often faced with ...
Posted by Michael Wonder on 04 Mar 2022
Science hasn’t shown these medications work. They’re being sold anyway.
3 March 2022 - Federal regulators are increasingly approving medicines before studies have shown they work, leaving patients at risk ...
Posted by Michael Wonder on 03 Mar 2022
PhRMA Statement on the State of the Union Address
1 March 2022 - The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the ...
Posted by Michael Wonder on 03 Mar 2022
Digital Therapeutics should be regulated with gold standard evidence
28 February 2022 - There is enormous growth in the digital health sector, illustrated by huge capital investment, and a massive ...
Posted by Michael Wonder on 02 Mar 2022
U.S. law makers seek answers on 'troubling' drug price increases
1 March 2022 - Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. law makers pressed the president of ...